Bronchodilator Response in COPDIntermittent Positive Pressure Breathing Trial (IPPB)

• Evaluated the BD response to inhaled isoproteronol in 985 subjects with COPD (asthma excluded)

• Pre and post- bronchodilator FEV1 evaluated every 3 months for 3 yrs.

• Key demographics:

  • Age: 60.9
  • Male: 79%
  • Smoking Status:
    • 54 pack yrs
    • 40% current smokers
  • FEV1 (% predicted): 36 %

Anthonisen, et al. Am Rev Respir Dis, 1986;133:14-20.

Previous slide

Next slide

Back to first slide

View graphic version